Article info
PDFNeurological rarities
Autoimmune necrotising myopathy and HMGCR antibodies
- Correspondence to Dr Stuart Viegas, Neuromuscular Unit, Department of Neurology, Charing Cross Hospital, London W6 8RF, UK; stuart.viegas{at}nhs.net
Citation
Autoimmune necrotising myopathy and HMGCR antibodies
Publication history
- Accepted January 14, 2018
- First published February 8, 2018.
Online issue publication
March 27, 2018
Article Versions
- Previous version (27 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Anti-HMGCR myopathy: barriers to prompt recognition
- Persisting weakness after withdrawal of a statin
- Myopathy with antibodies to the signal recognition particle: clinical and pathological features
- Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
- Statin-related myopathies
- Anti-HMGCR myopathy presenting with acute systolic heart failure
- Toxic and drug-induced myopathies
- Immune-mediated necrotising myopathy: a rare cause of hyperCKaemia
- Clinical features of the myasthenic syndrome arising from mutations in GMPPB
- Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy